Hologic, Inc. (HOLX)

Hologic, Inc. was a medical technology company focused on women's health, with headquarters in Marlborough, Massachusetts. It was founded in 1985 by S. David Ellenbogen and began with bone densitometry products. The company grew into a diversified developer and manufacturer of diagnostic, imaging and surgical products.

Over time it reported four main business areas. Diagnostics offered molecular and cytology products, including the Aptima assays for infectious diseases and the ThinPrep Pap test. Breast Health provided digital mammography, 3D tomosynthesis (marketed as Genius 3D Mammography), image analytics and biopsy guidance. GYN Surgical included NovaSure for endometrial ablation and the MyoSure tissue removal system, and Skeletal Health offered Horizon DXA bone density systems and mini C-arm imaging.

Hologic grew through a series of acquisitions, notably Cytyc in 2007, Third Wave Technologies, Gen-Probe in 2012, Cynosure (later divested), and Bolder Surgical. Its common stock traded on the Nasdaq Global Select Market under the symbol HOLX. The company benefited sharply during the pandemic from demand for SARS-CoV-2 molecular testing, after which diagnostics revenue normalized.

Steve MacMillan led the company as chief executive for many years, and Hologic regularly repurchased shares and invested in new product launches. In the mid-2020s the company's growth was moderated by the decline in COVID testing revenue and by pressures on capital equipment demand in some markets.

In 2025, Hologic announced a definitive agreement to be acquired by funds managed by Blackstone and TPG. Shareholders were to receive $76.00 per share in cash at closing, plus a non-transferable contingent value right of up to $3.00 per share tied to future revenue results, for a total of up to $79.00 per share.

The acquisition closed in April 2026 after approval by shareholders and clearance by regulators. A Form 25 was filed on April 7, 2026 to remove Hologic common stock from Nasdaq listing, and the company became privately held. The contingent value right was structured to be payable if specified revenue targets were met.